Abstract
Frontotemporal Dementia (FTD) is a prevalent form of early-onset dementia characterized by progressive neurodegeneration. It encompasses a group of heterogeneous disorders, including behavioral variant frontotemporal dementia (bvFTD), nonfluent variant primary progressive aphasia (nfvPPA), and semantic variant primary progressive aphasia (svPPA). Due to disease heterogeneity and overlapping symptoms, diagnosis of FTD and its subtypes still poses a challenge. Magnetic-resonance imaging (MRI) is commonly used to support the diagnosis of FTD. Using machine learning and multivariate statistics, we tested whether brain atrophy patterns are associated with severity of cognitive impairment, whether this relationship differs between the phenotypic subtypes, and whether we could use these brain patterns to classify patients according to their FTD variant.
A total of 136 patients (70 bvFTD, 36 svPPA, 30 nfvPPA) from the frontotemporal lobar degeneration neuroimaging initiative (FTLDNI) database underwent brain MRI and clinical and neuropsychological examination. Deformation-based morphometry (DBM), which offers increased sensitivity to subtle local differences in structural image contrasts was used to estimate regional cortical and subcortical atrophy. Atlas-based associations between DBM values and performance across different cognitive tests were assessed using partial least squares (PLS). We then applied linear regression models to discern the group differences regarding the relationship between atrophy and cognitive decline in the three FTD phenotypes. Lastly, we assessed whether the combination of neural and behavioral patterns in the latent variables identified in the PLS analysis could be used as features in a machine-learning model to predict FTD subtypes in patients.
Results revealed four significant latent variables that combined accounted for 86% of the shared covariance between cognitive and brain atrophy measures. PLS-based atrophy and behavioral patterns predicted the FTD phenotypes with a cross-validated accuracy of 89.12%, with high specificity (91.46-97.15%) and sensitivity (84.19-93.56%). When using only MRI measures and two behavioral tests in the PLS and classification algorithm, ensuring clinical feasibility, our model was similarly precise (83.62%, specificity 86.38-93.51%, sensitivity 76.17-87.50%). Here, including only atrophy or behavior patterns in the analysis led to prediction accuracies of 69.76% and 76.38%, respectively, highlighting the increased value of combining MRI and clinical measures in subtype classification.
We demonstrate that the combination of brain atrophy and clinical characteristics, and multivariate statistical methods can serve as an imaging biomarker for early disease phenotyping in FTD, whereby inclusion of DBM measures adds to the classification precision in the absence of extensive clinical testing.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AM is funded by Healthy Brains for Healthy Lives (HBHL) and Fonds de Recherche du Quebec Sante (FRQS). YZ reports receiving research funding from the HBHL, FRQS Chercheurs boursiers et chercheuses boursieres en Intelligence artificielle, as well as Natural Sciences and Engineering Research (NSERC) discovery grant. S.D. has been sponsored by Biogen, Novo Nordisk, Janssen, Alnylam, Wave Life Sciences, and Passage Bio; has received consulting fees from Eisai, QuRALIS, AI Therapeutics, and Eli Lilly; has received payments from Eisai; and has participated in the boards of IntelGenX and AVIADO Bio. SV is supported by the FRQS, the Alzheimers Association, the Canadian Institutes of Health Research (CIHR) and Brain Canada. MD reports receiving research funding from the HBHL, CIHR, and FRQS.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used data from the Neuroimaging in Frontotemporal Dementia (NIFD) cohort (https://memory.ucsf.edu/research-trials/research/allftd), available through https://ida.loni.usc.edu/login.jsp.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
NIFD MRI and clinical measures are available through https://ida.loni.usc.edu/login.jsp. Derived data supporting the findings of this study, including individual PLS scores, are available from the corresponding author on request.
